Duloxetine Capsule, Delayed Release
Product Images NDC 67877-263

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 67877-263). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ascend Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Duloxetine-structure (Duloxetine Structure)

Chemical structure of Duloxetine, showing the molecular arrangement including aromatic rings, a thiophene group, and an amine hydrochloride moiety.*

FDA Label Image

Fig1 (Duloxetine Figure1)

A Kaplan-Meier plot showing the proportion of patients with relapse over time from randomization (days) comparing placebo and duloxetine treatment groups. The graph displays time on the x-axis ranging up to 250 days, and proportion of patients with relapse on the y-axis from 0 to 1, with separate curves for placebo (higher relapse rate) and duloxetine (lower relapse rate).*

FDA Label Image

Fig2 (Duloxetine Figure2)

A line graph depicting the proportion of patients with relapse over time in days from randomization. The graph compares two treatments, placebo and duloxetine, showing a higher relapse proportion for placebo than duloxetine over approximately 275 days.*

FDA Label Image

Fig3 (Duloxetine Fig3)

A line graph showing the percentage of patients improved with Duloxetine HCl 60 mg BD, 60 mg QD, 20 mg QD, and placebo over increasing percent improvement in pain from baseline. The x-axis represents percent improvement in pain, and the y-axis shows the percentage of patients improved. Duloxetine treatments show higher patient improvement percentages than placebo across the range.*

FDA Label Image

Fig4 (Duloxetine Fig4)

A line graph comparing the percentage of patients improved against percent improvement in pain from baseline for Duloxetine HCl 60mg taken twice daily (BD), Duloxetine HCl 60mg taken once daily (QD), and placebo. The graph shows the efficacy trends of these three groups across various levels of pain improvement.*

FDA Label Image

Duloxetine-fig-5 (Duloxetine Fig 5)

A line graph depicting the percentage of patients improved relative to percent improvement in pain from baseline. The chart compares Duloxetine HCL 60 mg taken twice daily, Duloxetine HCL 60 mg taken once daily, and placebo groups, showing differences in pain improvement percentages across various improvement thresholds.*

FDA Label Image

Duloxetine-fig-6 (Duloxetine Fig 6)

A line graph comparing the percentage of patients improved against percent improvement in pain from baseline for different oral Duloxetine HCL dosages (120 mg, 60 mg, 20 mg once daily) and placebo. The graph shows a decline in patient improvement percentage with increasing pain improvement, with Duloxetine lines above placebo.*

FDA Label Image

Duloxetine-fig7-a (Duloxetine Fig7 A)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline. Two lines represent treatment with Cymbalta 60 mg once daily and placebo, showing greater improvement in pain scores for the Cymbalta group across various pain improvement intervals.*

FDA Label Image

Duloxetine-fig7 (Duloxetine Fig7)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily and placebo. The y-axis shows the percentage of patients improved, and the x-axis indicates the percent improvement in pain from 0 to 100 percent.*

FDA Label Image

Duloxetine-fig8 (Duloxetine Fig8)

A line graph comparing the percentage of patients improved over different levels of percent improvement in pain from baseline, showing two groups: placebo and Duloxetine 60 mg once daily. The x-axis represents percent improvement in pain from baseline (BOCF), and the y-axis shows the percentage of patients improved.*

FDA Label Image

Duloxetine-fig10-a (Duloxetine Fig10 A)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily and placebo. The graph shows two lines representing the treatment and control groups over varying levels of pain improvement.*

FDA Label Image

Duloxetine (Duloxetine 20 1000 E)

Label for Duloxetine delayed-release capsules USP 20 mg by Ascend Laboratories, LLC, containing 1,000 capsules. The label includes storage instructions, a barcode, manufacturer details (Alkem Laboratories, Mumbai, India), and distributor information (Ascend Laboratories, Bedminster, NJ). It advises dispensing the Medication Guide to patients and highlights the capsule strength and prescription-only status.*

FDA Label Image

Duloxetine 30 mg (Duloxetine 30 100 F)

Label for Duloxetine delayed-release capsules USP, 30 mg strength, in a 100-capsule package. The label includes the Ascend Laboratories, LLC logo, NDC 67877-264-01, and states the product is Rx only. It notes the dosage form as delayed-release capsules and provides storage instructions. The label shows the manufacturer as Alkem Laboratories Ltd., Mumbai, India, and distributor Ascend Laboratories, Bedminster, NJ.*

FDA Label Image

Duloxetine 60 mg (Duloxetine 60 30 D)

Duloxetine delayed-release capsules USP 60 mg by Ascend Laboratories, LLC. The label includes dosage information, storage instructions, and cautions such as not using if the inner seal is missing or broken. The package contains 30 capsules and states it is Rx only. The label has a barcode and specifies manufacturing by Alkem Laboratories Ltd., Mumbai, India.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.